دورية أكاديمية
The proteasome inhibitor PS-341 in cancer therapy.
| العنوان: | The proteasome inhibitor PS-341 in cancer therapy. |
|---|---|
| المؤلفون: | Teicher BA; Dana-Farber Cancer Institute and Joint Center for Radiation Therapy, Boston, Massachusetts 02115, USA. TEICHER_BEVERLY_A@LILLY.COM, Ara G, Herbst R, Palombella VJ, Adams J |
| المصدر: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 1999 Sep; Vol. 5 (9), pp. 2638-45. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Print ISSN: 1078-0432 (Print) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Denville, NJ : The Association, c1995- |
| مواضيع طبية MeSH: | Adenocarcinoma/*drug therapy , Antineoplastic Agents/*pharmacology , Boronic Acids/*pharmacology , Breast Neoplasms/*drug therapy , Dipeptides/*pharmacology , Protease Inhibitors/*pharmacology , Pyrazines/*pharmacology, Adenocarcinoma/radiotherapy ; Animals ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Boronic Acids/metabolism ; Bortezomib ; Breast Neoplasms/radiotherapy ; Cisplatin/administration & dosage ; Cyclophosphamide/administration & dosage ; Drug Synergism ; Humans ; Mammary Neoplasms, Experimental/drug therapy ; Mammary Neoplasms, Experimental/radiotherapy ; Mice ; Mice, Inbred BALB C ; Radiation-Sensitizing Agents/pharmacology ; Tumor Cells, Cultured ; Ubiquitins/metabolism |
| مستخلص: | The anticancer activity of the boronic acid dipeptide proteasome inhibitor PS-341 was examined in vitro and in vivo. PS-341 was a potent cytotoxic agent toward MCF-7 human breast carcinoma cells in culture, producing an IC90 of 0.05 microM on 24 h of exposure to the drug. In the EMT-6 tumor cell survival assay, PS-341 was equally cytotoxic administered p.o. or by i.p. injection up to a dose of 2 mg/kg. PS-341 was also toxic to the bone marrow colony-forming unit-granulocyte macrophage. PS-341 increased the tumor cell killing of radiation therapy, cyclophosphamide, and cisplatin in the EMT-6/Parent tumor, but was not able to overcome the in vivo resistance of the EMT-6/CTX and EMT-6/CDDP tumors. In the tumor growth delay assay, PS-341 administered p.o. had antitumor activity against the Lewis lung carcinoma, both primary and metastatic disease. In combination, regimens with 5-fluorouracil, cisplatin, Taxol and adriamycin, PS-341 seemed to produce primarily additive tumor growth delays against the s.c. tumor and was highly effective against disease metastatic to the lungs. The proteasome is an interesting new target for cancer therapy, and the proteasome inhibitor PS-341 warrants continued investigation in cancer therapy. |
| المشرفين على المادة: | 0 (Antineoplastic Agents) 0 (Boronic Acids) 0 (Dipeptides) 0 (Protease Inhibitors) 0 (Pyrazines) 0 (Radiation-Sensitizing Agents) 0 (Ubiquitins) 69G8BD63PP (Bortezomib) 8N3DW7272P (Cyclophosphamide) Q20Q21Q62J (Cisplatin) |
| تواريخ الأحداث: | Date Created: 19990928 Date Completed: 19991122 Latest Revision: 20220227 |
| رمز التحديث: | 20240829 |
| PMID: | 10499643 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!